Abstract
Thyroid cancer originates from epithelial and from parafollicular C-cells. Distant metastases occur in about 5–10 % of patients. RAI therapy and TSH suppressive therapy have an established role in the management of disseminated thyroid cancer, yet in most of these patients disease progress is only a matter of time. Disease progression is usually accompanied by dedifferentiation of cancer cells and standard therapies are no more effective. In this chapter new molecular backgrounds and clinical data on novel redifferentiating agents are discussed.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Ain KB, Egorin MJ, DeSimone PA (2000) Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative anaplastic thyroid cancer health intervention trials (CATCHIT) group. Thyroid 10:587–594
Arturi F, Russo D, Schlumberger M, du Villard JA, Caillou B, Vigneri P, Wicker R, Chiefari E, Suarez HG, Filetti S (1998) Iodide symporter gene expression in human thyroid tumors. J Clin Endocrinol Metab 83:2493–2496
Bassi V, Vitale M, Feliciello A, De RS, Rossi G, Fenzi G (1995) Retinoic acid Induces intercellular adhesion molecule-1 hyperexpression in human thyroid carcinoma cell lines. J Clin Endocrinol Metab 80:1129–1135
Boerner AR, Petrich T, Weckesser E, Fricke H, Hofmann M, Otto D, Weckesser M, Langen KJ, Knapp WH (2002) Monitoring isotretinoin therapy in thyroid cancer using 18F-FDG PET. Eur J Nucl Med Mol Imaging 29:231–236
Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, Bidart JM (1998) Na+/I− symporter distribution in human thyroid tissues: an immunohistochemical study. J Clin Endocrinol Metab 83:4102–4106
Fernandez CA, Puig-Domingo M, Lomena F, Estorch M, Camacho M, V, Bittini A L, Marazuela M, Santamaria J, Castro J, Martinez d, I, Moraga I, Martin T, Megia A, Porta M, Mauricio D and Halperin I (2009) Effectiveness of retinoic acid treatment for redifferentiation of thyroid cancer in relation to recovery of radioiodine uptake. J Endocrinol Invest 32:228–233
Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L (1990) All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clin Results Blood 76:1704–1709
Coelho SM, Corbo R, Buescu A, Carvalho DP, Vaisman M (2004) Retinoic acid in patients with radioiodine non-responsive thyroid carcinoma. J Endocrinol Invest 27:334–339
Coelho SM, Vaisman M, Carvalho DP (2005) Tumour re-differentiation effect of retinoic acid: a novel therapeutic approach for advanced thyroid cancer. Curr Pharm Des 11:2525–2531
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM (2006) Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 16:109–142
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM (2009) Revised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214
Courbon F, Zerdoud S, Bastie D, Archambaud F, Hoff M, Eche N, Berry I, Caron P (2006) Defective efficacy of retinoic acid treatment in patients with metastatic thyroid carcinoma. Thyroid 16:1025–1031
De Besi P, Busnardo B, Toso S, Girelli ME, Nacamulli D, Simioni N, Casara D, Zorat P, Fiorentino MV (1991) Combined chemotherapy with bleomycin, adriamycin, and platinum in advanced thyroid cancer. J Endocrinol Invest 14:475–480
Demierre MF, Higgins PD, Gruber SB, Hawk E, Lippman SM (2005) Statins and cancer prevention. Nat Rev Cancer 5:930–942
Dohan O, Baloch Z, Banrevi Z, Livolsi V, Carrasco N (2001) Rapid communication: predominant intracellular overexpression of the Na(+)/I(−) symporter (NIS) in a large sampling of thyroid cancer cases. J Clin Endocrinol Metab 86:2697–2700
Durand S, Ferraro-Peyret C, Joufre M, Chave A, Borson-Chazot F, Selmi-Ruby S, Rousset B (2009) Molecular characteristics of papillary thyroid carcinomas without BRAF mutation or RET/PTC rearrangement: relationship with clinico-pathological features. Endocr Relat Cancer 16:467–481
Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, Tosi E, Cavaliere A, Gulino A, Filetti S, Russo D (2007) BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab 92:2840–2843
Elisei R, Vivaldi A, Agate L, Ciampi R, Molinaro E, Piampiani P, Romei C, Faviana P, Basolo F, Miccoli P, Capodanno A, Collecchi P, Pacini F, Pinchera A (2005) All-trans-retinoic acid treatment inhibits the growth of retinoic acid receptor beta messenger ribonucleic acid expressing thyroid cancer cell lines but does not reinduce the expression of thyroid-specific genes. J Clin Endocrinol Metab 90:2403–2411
Fagin JA (2004) How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy. J Endocrinol 183:249–256
Farol LT, Hymes KB (2004) Bexarotene: a clinical review. Expert Rev Anticancer Ther 4:180–188
Frohlich E, Machicao F, Wahl R (2005) Action of thiazolidinediones on differentiation, proliferation and apoptosis of normal and transformed thyrocytes in culture. Endocr Relat Cancer 12:291–303
Giguere V (1994) Retinoic acid receptors and cellular retinoid binding proteins: complex interplay in retinoid signaling. Endocr Rev 15:61–79
Gregory PJ, Wang X, Allard BL, Sahin M, Wang XL, Hay ID, Hiddinga HJ, Deshpande SS, Kroll TG, Grebe SK, Eberhardt NL, McIver B (2004) The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-Type PPARgamma inhibition. Oncogene 23:3634–3641
Gruning T, Tiepolt C, Zophel K, Bredow J, Kropp J, Franke WG (2003) Retinoic acid for redifferentiation of thyroid cancer–does it hold its promise? Eur J Endocrinol 148:395–402
Grunwald F, Menzel C, Bender H, Palmedo H, Otte R, Fimmers R, Risse J, Biersack HJ (1998a) Redifferentiation therapy-induced radioiodine uptake in thyroid cancer. J Nucl Med 39:1903–1906
Grunwald F, Pakos E, Bender H, Menzel C, Otte R, Palmedo H, Pfeifer U, Biersack HJ (1998b) Redifferentiation therapy with retinoic acid in follicular thyroid cancer. J Nucl Med 39:1555–1558
Handkiewicz-Junak D, Roskosz J, Hasse-Lazar K, Szpak-Ulczok S, Puch Z, Kukulska A, Olczyk T, Piela A, Paliczka-Cieslik E, Jarzab B (2009) 13-Cis-Retinoic acid re-differentiation therapy and recombinant human thyrotropin-aided radioiodine treatment of non-functional metastatic thyroid cancer: a single-center, 53-patient phase 2 study. Thyroid Res 2:8
Handkiewicz-Junak D, Czarniecka A, Jarzab B (2010) Molecular prognostic markers in papillary and follicular thyroid cancer: current status and future directions. Mol Cell Endocrinol 322:8–28
Haugen BR (1999) Management of the patient with progressive radioiodine non-responsive disease. Semin Surg Oncol 16:34–41
Haugen BR (2006) Does the metabolic activity of metastatic thyroid carcinoma correlate with prognosis? Nat Clin Pract Endocrinol Metab 2:488–489
Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR III, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84:3877–3885
Haugen BR, Larson LL, Pugazhenthi U, Hays WR, Klopper JP, Kramer CA, Sharma V (2004) Retinoic acid and retinoid X receptors are differentially expressed in thyroid cancer and thyroid carcinoma cell lines and predict response to treatment with retinoids. J Clin Endocrinol Metab 89:272–280
Havekes B, Schroder van der Elst JP, van der PG, Goslings BM, Romijn JA, Smit JW (2000) Beneficial effects of retinoic acid on extracellular matrix degradation and attachment behaviour in follicular thyroid carcinoma cell lines. J Endocrinol 167:229–238
Hoang-Vu C, Bull K, Schwarz I, Krause G, Schmutzler C, Aust G, Kohrle J, Dralle H (1999) Regulation of CD97 protein in thyroid carcinoma. J Clin Endocrinol Metab 84:1104–1109
Hoftijzer H, Heemstra KA, Morreau H, Stokkel MP, Corssmit EP, Gelderblom H, Weijers K, Pereira AM, Huijberts M, Kapiteijn E, Romijn JA, Smit JW (2009) Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 161:923–931
Hundahl SA, Fleming ID, Fremgen AM, Menck HR (1998) A national cancer data base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995 [See Commetns]. Cancer 83:2638–2648
Kebebew E, Lindsay S, Clark OH, Woeber KA, Hawkins R, Greenspan FS (2009) Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer. Thyroid 19:953–956
Kim WG, Kim EY, Kim TY, Ryu JS, Hong SJ, Kim WB, Shong YK (2009) Redifferentiation therapy with 13-Cis retinoic acids in radioiodine-resistant thyroid cancer. Endocr J 56:105–112
Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T (2001) Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(−) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430–3435
Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH (2009) Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 27:1675–1684
Koh CS, Ku JL, Park SY, Kim KH, Choi JS, Kim IJ, Park JH, Oh SK, Chung JK, Lee JH, Kim WH, Kim CW, Cho BY, Park JG (2007) Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol 264:118–127
Kroll TG, Sarraf P, Pecciarini L, Chen CJ, Mueller E, Spiegelman BM, Fletcher JA (2000) PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [Corrected]. Science 289:1357–1360
Lazar V, Bidart JM, Caillou B, Mahe C, Lacroix L, Filetti S, Schlumberger M (1999) Expression of the Na+/I− symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 84:3228–3234
Liu YY, Stokkel MP, Pereira AM, Corssmit EP, Morreau HA, Romijn JA, Smit JW (2006) Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur J Endocrinol 154:525–531
Lotan R (1991) Retinoids as modulators of tumor cells invasion and metastasis. Semin Cancer Biol 2:197–208
Luong QT, O’Kelly J, Braunstein GD, Hershman JM, Koeffler HP (2006) Antitumor activity of suberoylanilide hydroxamic acid against thyroid cancer cell lines in vitro and in vivo. Clin Cancer Res 12:5570–5577
McBurney MW, Costa S, Pratt MA (1993) Retinoids and cancer: a basis for differentiation therapy. Cancer Invest 11:590–598
Oyen WJ, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B (2007) Targeted therapy in nuclear medicine–current status and future prospects. Ann Oncol 18:1782–1792
Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A (2001) Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 86:4092–4097
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:787–803
Peyssonnaux C, Eychene A (2001) The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 93:53–62
Riesco-Eizaguirre G, Santisteban P (2007) Molecular biology of thyroid cancer initiation. Clin Transl Oncol 9:686–693
Rigas JR, Dragnev KH (2005) Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene. Oncologist 10:22–33
Ringel MD (2006) Phase II study of histone deacetylase inhibitor SAHA in patients with metastatic thyroid cancer. Thyroid 14:928–929
Rochaix P, Monteil-Onteniente S, Rochette-Egly C, Caratero C, Voigt JJ, Jozan S (1998) Reduced expression of retinoic acid receptor beta protein (RAR Beta) in human papillary thyroid carcinoma: immunohistochemical and western blot study. Histopathology 33:337–343
Ruegemer JJ, Hay ID, Bergstralh EJ, Ryan JJ, Offord KP, Gorman CA (1988) Distant metastases in differentiated thyroid carcinoma: a multivariate analysis of prognostic variables. J Clin Endocrinol Metab 67:501–508
Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, Muramatsu A, Onaya T (1998) Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 101:1296–1300
Santoro M, Melillo RM, Fusco A (2006) RET/PTC activation in papillary thyroid carcinoma: European journal of endocrinology prize lecture. Eur J Endocrinol 155:645–653
Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, Naoe T, Lengfelder E, Buchner T, Dohner H, Burnett AK, Lo-Coco F (2009) Management of acute promyelocytic Leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 113:1875–1891
Schlumberger M, Challeton C, De VF, Travagli JP, Gardet P, Lumbroso JD, Francese C, Fontaine F, Ricard M, Parmentier C (1996) Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med 37:598–605
Schmutzler C, Winzer R, Meissner-Weigl J, Kohrle J (1997) Retinoic acid increases sodium/iodide symporter MRNA levels in human thyroid cancer cell lines and suppresses expression of functional symporter in nontransformed FRTL-5 rat thyroid cells. Biochem Biophys Res Commun 240:832–838
Schmutzler C, Brtko J, Winzer R, Jakobs TC, Meissner-Weigl J, Simon D, Goretzki PE, Kohrle J (1998) Functional retinoid and thyroid hormone receptors in human thyroid-carcinoma cell lines and tissues. Int J Cancer 76:368–376
Schmutzler C, Schmitt TL, Glaser F, Loos U, Kohrle J (2002) The promoter of the human sodium/iodide-symporter gene responds to retinoic acid. Mol Cell Endocrinol 189:145–155
Schmutzler C, Hoang-Vu C, Ruger B, Kohrle J (2004) Human thyroid carcinoma cell lines show different retinoic acid receptor repertoires and retinoid responses. Eur J Endocrinol 150:547–556
Schreck R, Schnieders F, Schmutzler C, Kohrle J (1994) Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 79:791–798
Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ (2008) Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 359:31–42
Short SC, Suovuori A, Cook G, Vivian G, Harmer C (2004) A phase II study using retinoids as redifferentiation agents to increase iodine uptake in metastatic thyroid cancer. Clin Oncol (R Coll Radiol) 16:569–574
Simon D, Koehrle J, Reiners C, Boerner AR, Schmutzler C, Mainz K, Goretzki PE, Roeher HD (1998) Redifferentiation therapy with retinoids: therapeutic option for advanced follicular and papillary thyroid carcinoma. World J Surg 22:569–574
Simon D, Korber C, Krausch M, Segering J, Groth P, Gorges R, Grunwald F, Muller-Gartner HW, Schmutzler C, Kohrle J, Roher HD, Reiners C (2002) Clinical impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. Eur J Nucl Med Mol Imaging 29:775–782
Soares P, Sobrinho-Simoes M (1995) Recent advances in cytometry, cytogenetics and molecular genetics of thyroid tumours and tumour-like lesions. Pathol Res Pract 191:304–317
Sobrinho-Simoes M, Preto A, Rocha AS, Castro P, Maximo V, Fonseca E, Soares P (2005) Molecular pathology of well-differentiated thyroid carcinomas. Virchows Arch 447:787–793
Takiyama Y, Miyokawa N, Sugawara A, Kato S, Ito K, Sato K, Oikawa K, Kobayashi H, Kimura S, Tateno M (2004) Decreased expression of retinoid X receptor isoforms in human thyroid carcinomas. J Clin Endocrinol Metab 89:5851–5861
Tallini G (2002) Molecular pathobiology of thyroid neoplasms. Endocr Pathol 13:271–288
Tepmongkol S, Keelawat S, Honsawek S, Ruangvejvorachai P (2008) Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 18:697–704
Van Herle AJ, Agatep ML, Padua DN III, Totanes TL, Canlapan DV, Van Herle HM, Juillard GJ (1990) Effects of 13 cis-retinoic acid on growth and differentiation of human follicular carcinoma cells (UCLA R0 82W-1) in vitro. J Clin Endocrinol Metab 71:755–763
Vecchio G, Santoro M (2000) Oncogenes and thyroid cancer. Clin Chem Lab Med 38:113–116
Venkataraman GM, Yatin M, Marcinek R, Ain KB (1999) Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I− symporter gene methylation status. J Clin Endocrinol Metab 84:2449–2457
Wang CY, Zhong WB, Chang TC, Lai SM, Tsai YF (2003) Lovastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, induces apoptosis and differentiation in human anaplastic thyroid carcinoma cells. J Clin Endocrinol Metab 88:3021–3026
Wong WW, Dimitroulakos J, Minden MD, Penn LZ (2002) HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia 16:508–519
Woyach JA, Kloos RT, Ringel MD, Arbogast D, Collamore M, Zwiebel JA, Grever M, Villalona-Calero M, Shah MH (2009) Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab 94:164–170
Ying H, Suzuki H, Zhao L, Willingham MC, Meltzer P, Cheng SY (2003) Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis. Cancer Res 63:5274–5280
Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, Niederle B (2002) Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma—surgery or conventional therapy? Clin Endocrinol (Oxf) 56:377–382
Zhong WB, Liang YC, Wang CY, Chang TC, Lee WS (2005) Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling. Endocr Relat Cancer 12:615–629
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Luster, M., Handkiewicz-Junak, D., Smit, J.W. (2012). Redifferentiation Therapy in Thyroid Cancer. In: Baum, R. (eds) Therapeutic Nuclear Medicine. Medical Radiology(). Springer, Berlin, Heidelberg. https://doi.org/10.1007/174_2012_742
Download citation
DOI: https://doi.org/10.1007/174_2012_742
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-36718-5
Online ISBN: 978-3-540-36719-2
eBook Packages: MedicineMedicine (R0)